Generate Biomedicines, Inc. GENB
13.49 USD -0.29 (-2.10%)
At closeNov 11, 2026, 5:34 PM EST
13.40 -0.09 -0.67%
After hours · Nov 11, 5:34 PM ET
13.48 Day range 14.00
11.00 52-week range 22.67
- YTD
- +6.64%
- 1 year
- +6.64%
News
globenewswire.com Generate Biomedicines to Participate in November Investor Conferences SOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at…
defenseworld.net Banque Pictet & Cie SA Buys New Position in Generate Biomedicines Inc $GENB Banque Pictet and Cie SA purchased a new stake in Generate Biomedicines Inc (NASDAQ: GENB) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).…
benzinga.com Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market Generate Biomedicines & Zealand Pharma team up to develop AI-engineered protein therapies for obesity & metabolic diseases.
benzinga.com Generate Biomedicines To Receive $30M Upfront, Up To $1.2B In Milestones And Tiered Royalties Under Zealand Pharma Collaboration Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today announced a multi-target strategic collaboration with Zealand Pharma A/S (NASDAQ:ZEAL), a biotechnology company transforming the future of…
globenewswire.com Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases…
globenewswire.com Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine Zealand Pharma's expertise in metabolic health with Generate's proprietary generative AI platform to create multispecific drug candidates with tailored biological functions
seekingalpha.com Generate Biomedicines: The Dosing Interval Is The Moat, Not The Algorithm Generate Biomedicines offers a compelling long-acting asthma biologic, golukibart (GB-0895), targeting twice-yearly dosing and broad phenotype efficacy. GENB leads the TSLP antagonist race with two…
benzinga.com HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB) with a Buy and maintains $30 price target.
defenseworld.net Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) and Generate Biomedicines (NASDAQ:GENB) Generate Biomedicines (NASDAQ: GENB - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
benzinga.com Roswell Park And Generate Biomedicines Announce First Patient Dosed In First-In-Human Clinical Trial Evaluating GB-5267, Investigational, Autologous IL-18 Armored CAR T-Cell Therapy Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trialsFirst patient treated in new clinical…
globenewswire.com Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical…
defenseworld.net Squarepoint Ops LLC Makes New $530,000 Investment in Generate Biomedicines Inc $GENB Squarepoint Ops LLC bought a new position in Generate Biomedicines Inc (NASDAQ: GENB) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and…
seekingalpha.com Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript- benzinga.com HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB) with a Buy and maintains $30 price target.
globenewswire.com Generate Biomedicines Inc. to Participate in September Investor Conferences SOMERVILLE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at…
benzinga.com Ulta Beauty To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday Wall Street analysts updated ratings for top names. Workday target raised, Ulta Beauty & Genasys targets lowered. See how others view these stocks.- benzinga.com HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $25 to $30.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock…
proactiveinvestors.com Generate Biomedicines stock jumps as post-IPO lock-up set to expire Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends…
proactiveinvestors.com Generate Biomedicines stock jumps as post-IPO lock-up set to expire Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO...- benzinga.com Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 73.2 percent increase over losses of…
globenewswire.com Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be…
fool.com This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It Generate Biomedicines had its IPO this past February. The company has had buy-in from Nvidia and Amgen.
fool.com Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It? The chipmaker has active interests in the healthcare market, including a partnership with Eli Lilly and an investment in small biotech Generate Biomedicines. Nvidia CEO Jensen Huang sees a powerful…
benzinga.com Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock, Optimum Communications, Cronos, and others also drop.
benzinga.com Why Constellation Brands Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Constellation Brands (NYSE: STZ) rose in pre-market trading after reporting strong Q1 earnings and raising its FY27 guidance. Other gainers include DXF, EHGO, JEM, TC, VMAR, LGPS, BTOG, LUNR, and BE.…
prnewswire.com AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts Newly Constructed Phase 2 now 100% Leased Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination BOSTON, June 22, 2026 /PRNewswire/ -- IQHQ, Inc. today announced…
fool.com A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.
prnewswire.com Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday,…- benzinga.com Morgan Stanley Maintains Overweight on Generate Biomedicines, Raises Price Target to $22 Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweight and raises the price target from $20 to $22.
benzinga.com HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $25 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $16 to $25.- benzinga.com Generate Biomedicines Q1 EPS $(1.07) Misses $(0.54) Estimate, Sales $7.224M Beat $5.938M Estimate Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.54) by 98.15 percent. This is a 33.95 percent increase over…
prnewswire.com Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in…
benzinga.com This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top names. Check our analyst ratings page for upgrades, downgrades, initiations. See opinions on CRDO.
benzinga.com HC Wainwright & Co. Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $16 HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $16.
benzinga.com Goldman Sachs Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $26 Goldman Sachs analyst Salveen Richter initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $26.- benzinga.com Morgan Stanley Initiates Coverage On Generate Biomedicines with Overweight Rating, Announces Price Target of $20 Morgan Stanley analyst Sean Laaman initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating and announces Price Target of $20.
- benzinga.com Piper Sandler Initiates Coverage On Generate Biomedicines with Overweight Rating, Announces Price Target of $24 Piper Sandler analyst Edward Tenthoff initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating and announces Price Target of $24.
benzinga.com Cantor Fitzgerald Initiates Coverage On Generate Biomedicines with Overweight Rating Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating.
benzinga.com This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrades, and initiations. KBH, SOLV, SDHC, GENB coverage initiated.- benzinga.com Guggenheim Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $30 Guggenheim analyst Seamus Fernandez initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $30.
benzinga.com Preview: Generate Biomedicines, Inc Set To IPO Tomorrow